| pubmed-article:9458105 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C0023440 | lld:lifeskim |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C1511617 | lld:lifeskim |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C0086982 | lld:lifeskim |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C1511939 | lld:lifeskim |
| pubmed-article:9458105 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:9458105 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9458105 | pubmed:dateCreated | 1998-2-24 | lld:pubmed |
| pubmed-article:9458105 | pubmed:abstractText | Hexamethylenebisacetamide (HMBA) is a potent differentiation inducer of murine erythroleukemia cells. Immunoprecipitation followed by Western blotting with an anti-phosphotyrosine (P-Tyr) antibody revealed that HMBA increased P-Tyr levels and/or amounts of several proteins containing P-Tyr in F5-5, a murine erythroleukemia cell line. Among these proteins, we identified a Mr 130,000 protein to be Janus-activated kinase 2 (JAK2). HMBA induced tyrosine phosphorylation of JAK2 and signal transducers and activators of transcription 5 (STAT5) but not other JAKs or STATs. This phosphorylation was apparent 12 h after treatment, maximal at 24 h, and persisted for at least 96 h. Consistently, HMBA increased STAT5 DNA-binding activities. Other chemical inducers, DMSO and butyrate, also induced a sustained activation of JAK2/STAT5, whereas fetal calf serum and erythropoietin induced transient activation but not differentiation. Furthermore, overexpression of a dominant-negative form of STAT5 inhibited the chemically induced differentiation. These results suggest that persistent activation of the signaling pathway plays a significant role in the inducer-mediated differentiation. Our data also suggest that molecular mechanisms for the inducer-mediated activation of JAK2 are independent of cytokine receptor-mediated activation mechanisms. We tentatively conclude that cytokine signaling is an important target of chemical inducers in these cells. | lld:pubmed |
| pubmed-article:9458105 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9458105 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9458105 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9458105 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9458105 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:9458105 | pubmed:author | pubmed-author:YamashitaTT | lld:pubmed |
| pubmed-article:9458105 | pubmed:author | pubmed-author:BRUCKM AMA | lld:pubmed |
| pubmed-article:9458105 | pubmed:author | pubmed-author:MiyajimaAA | lld:pubmed |
| pubmed-article:9458105 | pubmed:author | pubmed-author:WakaoHH | lld:pubmed |
| pubmed-article:9458105 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9458105 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9458105 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:9458105 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9458105 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9458105 | pubmed:pagination | 556-61 | lld:pubmed |
| pubmed-article:9458105 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:meshHeading | pubmed-meshheading:9458105-... | lld:pubmed |
| pubmed-article:9458105 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9458105 | pubmed:articleTitle | Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line. | lld:pubmed |
| pubmed-article:9458105 | pubmed:affiliation | Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Japan. y-taka@hgc.ims.u-tokyo.ac.jp | lld:pubmed |
| pubmed-article:9458105 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9458105 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9458105 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9458105 | lld:pubmed |
